Novel developments in angiogenesis cancer therapy.
A greater understanding of the factors and pathways controlling angiogenesis in tumours has allowed the development of a number of agents that selectively inhibit the pathways mediating that activity. The results to date of clinical trials with such agents and future research opportunities are reviewed.
Hirte
H W
HW
Department of Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario. hal.hirte@jcc.hhsc.ca